Celgene Corp. (CELG)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

86 MORRIS AVENUE SUMMIT, NJ 07901

Celgene is a biopharmaceutical company, engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. Co.'s commercial stage products include: REVLIMID, for the treatment in combination with dexamethasone for multiple myeloma patients; THALOMID, for the treatment of patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum, and as maintenance therapy for prevention of the cutaneous manifestation recurrence; and VIDAZA, that reverse the effects of deoxyribonucleic acid hypermethylation and promote gene re-expression.

Data based on most recent fiscal year report
Market Cap68.363 Billion Shares Outstanding787.32 Million Avg Volume8.606 Million
1-Yr BETA vs S&P TR Current Ratio4.99 Quick Ratio4.8
View SEC Filings from CELG instead.
Q2 2019 All Institutions Hedge Funds 1
To trade CELG now:
Filers who had this stock in their top 10: 97 47 (4.86%)
13F Filers holding this stock: 1241 129 (13.33%)
Aggregate 13F shares on 06/30/2019: 512.432 Million 110.487 Million
Aggregate 13F shares on 03/31/2019: 529.579 Million 113.705 Million
Percent change: -3.24% -2.83%
Funds creating new positions: 82 13
Funds Adding to an existing position: 338 54
Funds closing out their position: 163 32
Funds reducing their position: 608 46
Heat Map Ranking for 06/30/2019 79
Heat Map Ranking for 03/31/2019 91
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding CELG (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

11.3 Thousand total shares from 2 transactions

Exercise Derivative Conversion (M)

4.5 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GRYSKA DAVID W

  • Director
48,013 2019-10-01 0

FOUSE JACQUALYN A

  • Director
2,831 2019-09-30 0

SMITH SCOTT ANDREW

  • Director
24,976 2019-09-30 0

CURRAN TERRIE SEE REMARKS

3,081 2019-09-18 6

WEILAND JOHN H

  • Director
666 2019-09-15 1

BONNEY MICHAEL W

  • Director
7,051 2019-09-09 2

MARIO ERNEST

  • Director
280,779 2019-08-16 6

BARER SOL J

  • Director
0 2019-08-13 0

HALL PATRICIA HEMINGWAY

  • Director
0 2019-08-01 1

ELKINS DAVID V EVP, CHIEF FINANCIAL OFFICER

14,103 2019-08-01 2

COX CARRIE SMITH

  • Director
0 2019-07-30 1

REICIN ALISE

  • Director
0 2019-07-11 3

VESSEY RUPERT

0 2019-07-01 5

LOUGHLIN JAMES J

  • Director
0 2019-06-28 3

DANIEL THOMAS O

  • Director
0 2019-06-26 0

BARKER RICHARD W

13,337 2019-06-15 2

KARSEN PERRY A

  • Director
0 2019-06-13 0

FRIEDMAN MICHAEL A

19,847 2019-06-13 2

CASEY MICHAEL D

143,638 2019-06-13 2

HALLER JULIA A

2,409 2019-06-13 2

BISHOP HANS EDGAR

0 2019-06-03 1

KELLOGG PETER N

  • Director
0 2019-05-22 0

ALLES MARK J CEO, CHAIRMAN OF BOARD

227,518 2019-05-02 6

AHMED NADIM PRES., HEMATOLOGY AND ONCOLOGY

14,600 2019-05-02 5

BILLER JONATHAN EVP AND GENERAL COUNSEL

5,062 2019-05-02 3

HUGIN ROBERT J

  • Director
5,285 2019-04-30 0

MORIARTY THOMAS M EVP & GENERAL COUNSEL

  • Officer
110,371 2019-04-01 0

PEHL MICHAEL F. PRESIDENT AND CEO

  • Officer
0 2018-09-14 0

MASOUDI GERALD SEE REMARKS

13,698 2018-06-01 0

KAPLAN GILLA

76,301 2018-05-18 0

ROBB WALTER L

  • Director
0 2016-01-14 0

STEIN LAWRENCE V SEE REMARKS

  • Officer
14,568 2015-05-14 0

DRAKE RODMAN L

  • Director
No longer subject to file 2014-06-30 0

BURTON GRAHAM SEE REMARKS

  • Officer
0 2012-01-30 0

VAN HOEK ANDRE CONTROLLER AND CAO

  • Officer
0 2011-10-31 0

BROUWER AART SEE REMARKS

  • Officer
No longer subject to file 2010-12-31 0

HAYES ARTHUR H JR

  • Director
0 2010-02-09 0

MORGAN RICHARD C E

  • Director
3,602,216 2009-12-31 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

CURRAN TERRIE SEE REMARKS

2019-09-18 M 4,500 $58.33 a 13,493 3,081.00 direct

CURRAN TERRIE SEE REMARKS

2019-09-18 S 6,838 $98.31 d 2,155 3,081.00 direct

CURRAN TERRIE SEE REMARKS

2019-09-18 S 4,500 $98.20 d 8,993 3,081.00 direct

CURRAN TERRIE SEE REMARKS

2019-09-18 M 4,500 d 2,072 3,081.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments